Core Viewpoint - On May 26, 2025, Guoen Technology Co., Ltd. announced plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international capital operations and accelerate the establishment of a dual circulation pattern in the domestic and international markets [1][5]. Group 1: H-Share Issuance and Listing - The company plans to issue H-shares not exceeding 15% of the total share capital post-issuance, with proceeds allocated for establishing a Hong Kong regional headquarters, R&D investments, capacity expansion, strategic investments, and operational funding [1][5]. - The issuance and listing are subject to shareholder approval and regulatory approvals [1]. Group 2: Management Changes - On the same day, the company announced the resignation of two board members, Zhang Shide and Liu Shuyuan, due to personal reasons, with no impact on the board's legal quorum [1][2]. Group 3: Company Overview and Financial Performance - Founded in December 2000 and listed in June 2015, Guoen Group has developed a diversified portfolio in green petrochemicals, organic polymers, and health-related products, among others [4]. - In 2024, the company reported revenue of 19.219 billion yuan, a 10.21% increase from the previous year, and a net profit of 676 million yuan, up 45.18% year-on-year [4]. - The chemical industry segment generated 17.369 billion yuan, accounting for 90.38% of total revenue, while the health industry segment saw a decline in revenue [4]. Group 4: Recent Financial Results - In Q1 2025, the company reported revenue of 4.412 billion yuan, a slight decrease of 0.23%, and a net profit of 111 million yuan, down 9.79% year-on-year [5]. - As of March 31, 2025, total assets were 18.971 billion yuan, a 23.71% increase year-on-year, while total liabilities rose by 34.64% to 11.866 billion yuan [5].

Group 1 - Company plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to advance its global strategy and enhance its international capital operation platform [1] - The company aims to consider the interests of existing shareholders and the conditions of domestic and international capital markets when determining the timing and window for the issuance [1] - As of now, the company has developed a vertically integrated industrial cluster in new chemical materials, including green petrochemicals and biodegradable materials [1] Group 2 - In the large chemical industry, the company focuses on creating three main business engines: green petrochemical materials, organic polymer modified materials, and organic polymer composite materials [2] - The subsidiary, Dongbao Biological, specializes in the research, production, and sales of gelatin and collagen products, providing comprehensive solutions for downstream users [2] - The company operates both B2B and B2C business models, with B2B products including gelatin and collagen used in various sectors such as healthcare and beauty [2] Group 3 - In 2024, the company will focus on its main business, leveraging its vertical integration in the large chemical and health industries to drive growth [3] - The company expects to achieve a revenue of 19.22 billion yuan, a year-on-year increase of 10.21%, and a net profit of 676 million yuan, a year-on-year increase of 45.18% [3]